Accessibility Menu
Akari Therapeutics, Plc logo

Akari Therapeutics, Plc(NASDAQ) AKTX

Market Cap$9.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-99%
1 Year-81%
1 Month-23%
$8.00
+0.00%
+0.00Today
After hours$7.80-$0.20 (-2.50%)
Akari Therapeutics, Plc last closing stock price
MetricPriceDate
Last closeUSD 7.862026-07-31
Akari Therapeutics, Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.66%USD 8.702026-07-24
1 month-23.32%USD 10.252026-07-01
3 month+43.69%USD 5.472026-05-01
Year to date-32.01%USD 11.562025-12-31
1 year-80.92%USD 41.202025-07-31
3 year-96.33%USD 213.922023-08-01
5 year-99.39%USD 1,296.002021-07-30
Since inception-99.96%USD 19,800.002015-09-28

Akari Therapeutics, Plc Financials at a Glance

Market Cap

$9.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$28.05M

EPS (TTM)

-$18.86

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$8.00

Volume

14,598.421

Open

$7.80

Previous Close

$7.86

Daily Range

$7.80 - $8.10

52-Week Range

$3.02 - $49.60

Estimated Earnings Date

Aug 18, 2026

AKTX News

arrow pointing up and down with question mark

Is This Why Akari Therapetuics PLC Is Falling Today?

Brian FeroldiApr 24, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akari Therapeutics, Plc

Akari develops medicines for cancer and immune diseases. Its main products aim to help patients with serious health conditions. The company focuses on new treatments that target disease at the source.

What’s in the Akari Toolbox?

  • Antibody-Drug Conjugates (ADCs): Experimental cancer drugs that deliver targeted treatment to tumor cells. 0% of revenue (no sales).
  • AKTX-101: Pre-clinical drug for solid tumors like lung and breast cancer. 0% of revenue.
  • PHP-303: Small molecule drug for inflammation, acquired in 2024. 0% of revenue.
  • Nomacopan Programs: Legacy drugs for autoimmune diseases; development paused. 0% of revenue.

Growth Moves: Akari’s Strategic Shuffle

  • Acquired Peak Bio in November 2024, shifting focus to cancer drug development.
  • Raised $5.6 million in March 2025 and $3.0 million in August 2025 through private placements and note offerings.
  • Cut workforce by approximately 67% in May 2024 to reduce costs and focus on new pipeline.
  • Sought external partners for older drug programs after the merger.

Why Akari Is a Bit Different

Akari uses a unique approach in cancer drug development, focusing on new types of drug payloads. Its business model centers on early-stage research and partnerships for non-core assets. The company operates with a small team and a single focus on oncology.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Operating loss was $3 million in Q2 2025, down 58.1% from Q2 2024.
  • Net loss was $2 million in Q2 2025, down 74.9% from Q2 2024.
  • Cash used in operations was $3 million in Q2 2025, a 33.5% improvement year-on-year.

Bottom Line

Akari has shifted from immune disease drugs to early-stage cancer therapies. The company now relies on innovation, partnerships, and careful cost management to navigate ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Abizer Gaslightwala, MBA

Website

www.akaritx.com

Headquarters

Tampa, FL 33602, US

AKTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-123.29%

Return on Capital

-59.40%

Return on Assets

-82.76%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.14M

Volume

14.60K

Avg. Volume

783.95K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$29.51M

EBITDA

-$28.96M

Operating Cash Flow

-$10.88M

Capital Expenditure

-$3.68

Free Cash Flow

-$10.88M

Cash & ST Invst.

$2.77M

Total Debt

$732.00K

Akari Therapeutics, Plc Performance Analysis

Akari Therapeutics, Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Akari Therapeutics, Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Akari Therapeutics, Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -227.06-30.1%
20232023-12-31USD -82.11-63.8%
20242024-12-31USD -66.31-19.2%
20252025-12-31USD -20.60-68.9%
Akari Therapeutics, Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3055.9%
Q32025-09-30-226.7%
Q42025-12-3136.7%
Q12026-03-31-177.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$9.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.50M

N/A

Employees

6

N/A

Net Income

-$14.46M

-290.1%

EBITDA

-$15.25M

-317.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.77M

+7.2%

Total Debt

$732.00K

-60.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$732.00K

-60.3%

Return on Assets

-82.76%

N/A

Return on Invested Capital

-1.44%

N/A

Free Cash Flow

-$2.49M

-15.7%

Operating Cash Flow

-$2.49M

-15.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REVBRevelation Biosciences, Inc.
$0.95-4.56%
CDTCDT Equity Inc.
$2.93+9.33%
DRMADermata Therapeutics, Inc.
$1.17-0.85%
XAGELongevity Health Holdings Inc.
$0.23-6.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About AKTX

What is the current price of Akari Therapeutics, Plc?

Akari Therapeutics, Plc is trading at $7.86 per share.

What is the 52-week range for Akari Therapeutics, Plc?

Over the past 52 weeks, Akari Therapeutics, Plc has traded between $3.02 and $49.60.

How much debt does Akari Therapeutics, Plc have?

As of the most recent reporting period, Akari Therapeutics, Plc reported total debt of $732.00K.

How much cash does Akari Therapeutics, Plc have on hand?

Akari Therapeutics, Plc reported $2.83M in cash and cash equivalents in its most recent financial results.

What is Akari Therapeutics, Plc’s dividend yield?

Akari Therapeutics, Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services